First of its kind in Japan, Leave a Nest and Rhelixa launch “Epiclock ®︎ Co-Creation Project” – Scientifically measuring biological age to realize a society without fear of aging – ＜Presentation on Mar 8-9 at the Hyper Interdisciplinary Conference in 2024 Tokyo＞
Leave a Nest Co., Ltd. (Head Office: Shinjuku-ku, Tokyo; Founder and Group CEO: Dr. Yukihiro Maru; hereinafter “Leave a Nest”) and Rhelixa, Inc. (Representative Director, CEO/CTO: Ryo Nakaki, hereinafter “Rhelixa”), a leading epigenome analysis company, have launched the “Epiclock ®︎ Co-Creation Project” to establish a new concept of health different from calendar age, by measuring biological age based on the epigenome information and status of cells and tissues, thereby realizing a society without fear of aging
The World Health Organization (WHO) revised the International Classification of Diseases (ICD) for the first time in 30 years and added a new disease classification code, “aging-related”. Leave a Nest and Rhelixa have decided to jointly launch this project in response to the growing recognition that aging is a disease that should be treated and prevented, rather than the conventional belief that aging is an irreversible natural phenomenon.
This project aims to realize a society in which no one fears aging by promoting a new concept of age based on the condition of the body's cells and tissues (biological age), rather than on the number of years since birth (calendar age), which has been the common interpretation of age, and by slowing down biological aging.
Biological age is also referred to as age based on the state of cells, and is considered as an indicator that reflects the risk of aging-related diseases such as myocardial infarction, cancer, and Alzheimer's disease, in addition to the state of physical health and the progress of aging. The epigenetic clock, which calculates age based on epigenomic information in the form of DNA methylation, has been shown in recent studies to be the most promising and valid algorithm for measuring biological age. However, existing algorithms do not sufficiently take into account the genetic characteristics of Japanese people, and Rhelixa has now developed a unique algorithm that is adapted to the Japanese population. In the future, we will apply this algorithm and expand its application to the Asian region.
A press conference on this project and a panel session, “Lifetech Beyond Calendar Age, will be held on March 8-9, 2024, at the Hyper Interdisciplinary Conference in 2024 Tokyo (hosted by Leave a Nest). For a limited time, we are looking for companies that share the philosophy of the Epiclock Co-Creation Project to collaborate in research activities and solution development in order to find effective prescriptions for biological aging and accelerate the realization of a healthy and long-lived society.
Hyper Interdisciplinary Conference 2024 Tokyo
| Theme | Symbiosis and Emergence |
| Date & Time | March 8-9, 2024 |
| Place | Bellesalle Shinjuku Grand Conference Center |
| Session Time | March 9th（Sat）16:20-17:10 @Main Hall |
| Session Content | Lifetech Beyond Calendar Age -Redefining the Timeline of Life
Recently, for the first time in 30 years, the World Health Organization revised the International Classification of Diseases and added a new disease classification code called “aging-related”. Aging is no longer an “irreversible natural phenomenon” but rather a “disease” that should be treated and prevented. In this session, we will discuss how we can slow down the biological aging of the body and maintain a healthy state in a society where life expectancy is sure to increase in the future, and how lifetech can change the concept of age |
| Presenters | Ryo Nakaki, Rhelixa, Inc. Representative Director, CEO/CTO
Ken Higuchi, Mitsubishi Corporation S.L.C. Group CEO Office Dr. Yukihiro Maru, Leave a Nest Co., Ltd. Founder and Group CEO (Moderator) |
| For Registration | https://hic.lne.st/schedule/tokyo2024/ |
*Remarks
Rhelixa is promoting R&D business by analyzing omics information such as genome, epigenome, transcriptome, and metagenome with its unique technology and know-how. They registered to a Deep Tech Venture Ecosystem “TECH PLANTER” hosted by Leave a Nest. The company was selected as a finalist in the Biotech Grand Prix (formerly the Bioscience Grand Prix) and formed a capital and business alliance with Leave a Nest in 2017.
Leave a Nest will establish “Lifetech Grand Prix” as a new area of the TECH PLANTER in FY2024. It aims to solve, through a collection of science and technology, issues related to individual lives and ways of living that people face from birth to death, as exemplified by “aging.” https://lne.st/2024/02/06/lifetech-seminar/
■About Rhelixa (https://www.rhelixa.com/top-en/)
Rhelixa conducts basic research and develops products and solutions in the fields of biology, medicine, and pharmaceuticals, or provides contract services in these fields, utilizing its technologies cultivated through cutting-edge genomic and epigenomic analysis. Through integrated data analysis combining genomic, transcriptomic, and metagenomic data as well as epigenomic data obtained by next-generation sequencers, we predict detailed mechanisms of cell regulation and search for highly accurate markers. In addition, we provide an environment in which statistical analysis of data and creation of illustrations, which are necessary in all aspects of research and development, can be realized at anyone's fingertips without requiring basic knowledge in its field.
For inquiries regarding this matter
Leave a Nest Co., Ltd.
Corporate Planning Office
Attn. to Takeda, Matsubara
MAIL: [email protected]